Podcasts about crswnp

  • 32PODCASTS
  • 78EPISODES
  • 32mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Apr 24, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about crswnp

Latest podcast episodes about crswnp

The Itch: Allergies, Asthma & Immunology
#109 - Tezepelumab & Nasal Polyps: Inside the WAYPOINT Phase III Trial

The Itch: Allergies, Asthma & Immunology

Play Episode Listen Later Apr 24, 2025 27:31


Have you wondered why having more drug options matters for chronic rhinosinusitis with nasal polyps? In the inaugural episode of our new series, The Itch Review, co-hosts Kortney and Dr. Payel Gupta, along with special guest Dr. Michael Blaiss, unpack the journal article "Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps," published in the New England Journal of Medicine on March 1, 2025. This article is about the Phase III WAYPOINT trial of tezepelumab. Already approved for severe asthma, this once-monthly biologic is now showing promise in chronic rhinosinusitis with nasal polyps (CRSwNP). Over 52 weeks, 408 patients were randomized to receive 210 mg of tezepelumab every four weeks or placebo. Researchers tracked nasal-polyp scores, congestion, sense of smell, and rates of rescue surgery. In this episode, we provide a brief overview of what CRSwNP is, why inflammation drives polyp formation and how blocking TSLP fits into today's biologics options. We'll walk you through the WAYPOINT Phase III design, explain the primary and secondary endpoints, and translate the headline results into what they mean for real-world patients who've exhausted their treatment options. ➡️ Get the infographic here. What we cover in our episode about treating chronic rhinosinusitis with nasal polyps with tezepelumab CRSwNP basics & tezepelumab mechanism of action: How nasal polyps form and why targeting TSLP can reduce inflammation WAYPOINT design: 52-week, placebo-controlled Phase III study in 408 patients  Primary endpoints: Mean change in nasal polyp score and nasal-congestion score Secondary endpoints: Smell recovery, need for rescue surgery or systemic steroids, and quality-of-life measures Why choice matters: Every CRSwNP patient responds differently, and having more treatment options means more chances to find the right fit   Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

DocTalk Podcast
HCPLive Under 5 Audio Recap: Week of 03/09

DocTalk Podcast

Play Episode Listen Later Mar 16, 2025 3:39


Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 healthcare headlines for March 9-16, 2025: 1. CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial In the Phase 3 REDEFINE 2 trial, CagriSema showed weight reduction in adults with obesity or overweight and type 2 diabetes, outperforming placebo. 2. Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials The Phase 3 Launch-HTN and Phase 2 Advance-HTN trials showed lorundrostat effectively reduced blood pressure in uncontrolled or resistant hypertension with a favorable safety profile. 3. PharmaTher Receives New Early June FDA Goal Date for Ketamine PharmaTher announced the FDA set a new Priority Review goal date of June 4, 2025, for ketamine to treat anesthesia, pain, mental health, and neurological conditions. 4. FDA Awards Fast Track Designation to ATSN-201 Gene Therapy for XLRS The FDA granted Fast Track designation to ATSN-201 for X-linked retinoschisis, allowing Atsena Therapeutics to seek Priority Review for their gene therapy. 5. FDA Approves First Interchangeable Biosimilar for Omalizumab The FDA approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar to Xolair for asthma, CRSwNP, IgE-mediated food allergy, and CSU.

The Itch: Allergies, Asthma & Immunology
#102 - Comorbidities of Type 2 Inflammation

The Itch: Allergies, Asthma & Immunology

Play Episode Listen Later Feb 21, 2025 26:43


Why do conditions like asthma, nasal polyps, or eczema become more severe when they coexist? Kortney and Dr. Payel Gupta are joined by Dr. Michael Blaiss to explore the common thread linking multiple allergic and inflammatory diseases: Type 2 Inflammation. If you've ever wondered why certain conditions often appear together, this deep dive will help you connect the dots. Type 2 Inflammation is a hot topic in immunology because it's the engine that drives many allergic and inflammatory diseases. It's also the key to modern treatment strategies, including targeted biologic therapies. Dr. Blaiss explains how clinicians recognize multiple Type 2-driven conditions in the same patient, why it is important to know the connection between multiple conditions and Type 2 inflammation, and the big-picture benefits of treating inflammation aggressively to prevent complications. What We Cover in our Episode about The Diseases Related to Type 2 Inflammation Conditions Related to Type 2 Inflammation: Explore how chronic rhinosinusitis with nasal polyps (CRSwNP), rhinitis, asthma, atopic dermatitis (eczema), prurigo nodularis, eosinophilic esophagitis (EoE), and food allergies can all share a common inflammatory pathway. The Likelihood of Having Multiple Type 2 Conditions: How often do patients have more than one condition related to Type 2 Inflammation, and why is recognizing overlap a potential game-changer for diagnosis and treatment? Treating the Root Inflammation vs. Individual Symptoms: Discover how clinicians decide whether to address each condition separately or tackle the underlying Type 2 inflammatory process affecting them all. Markers & Personalized Medicine: Dr. Blaiss discusses whether potential tests, such as eosinophil counts or IgE levels, can confirm Type 2 inflammation. He also explains how knowing you have Type 2 Inflammation can help guide targeted therapy. Prevention & Aggressive Intervention: Understand why it's crucial to treat inflammation early to reduce the risk of developing multiple Type 2 conditions and how this proactive approach benefits long-term health. Want to know more? Type 2 Inflammation Overview – Explains the role of Type 2 inflammation in conditions like asthma and nasal polyps. This podcast is for informational purposes only and does not substitute for professional medical advice. If you have any medical concerns, always consult with your healthcare provider. Produced in partnership with The Allergy & Asthma Network. Thanks to Sanofi and Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
John V. Bosso, MD, FAAAAI - Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 17, 2025 55:39


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
John V. Bosso, MD, FAAAAI - Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Feb 17, 2025 55:39


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
John V. Bosso, MD, FAAAAI - Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 17, 2025 55:39


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
John V. Bosso, MD, FAAAAI - Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 17, 2025 55:39


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Medical Industry Feature
CRSwNP: Exploring the Role of Nasal Epithelium and Epithelial Cytokines

Medical Industry Feature

Play Episode Listen Later Feb 3, 2025


Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.​3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.​3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975. van der Veen J, et al. Allergy. 2017;72:282-290. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141. ©2024 Amgen and AstraZeneca. All rights reserved.US-96000 Last Updated 12/24

Medical Industry Feature
CRSwNP: The Critical Role of the Epithelium and Epithelial Cytokines

Medical Industry Feature

Play Episode Listen Later Jan 21, 2025


In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP. ©2025 Amgen and AstraZeneca. All rights reserved.US-94728 Last Updated 1/25

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Claus Bachert, MD, PhD / Cecelia Damask, DO - Managing CRSwNP With Biologic Therapies: A Global Dialogue

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Play Episode Listen Later Dec 20, 2024 18:43


Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

CME in Minutes: Education in Primary Care
Claus Bachert, MD, PhD / Cecelia Damask, DO - Managing CRSwNP With Biologic Therapies: A Global Dialogue

CME in Minutes: Education in Primary Care

Play Episode Listen Later Dec 20, 2024 18:43


Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Stella Lee, MD - Biologic Therapies for Chronic Rhinosinusitis With Nasal Polyps: Practical, Patient-Centered Perspectives for Providers

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Play Episode Listen Later Dec 12, 2024 19:19


Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Kathleen M. Buchheit, MD - Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 15, 2024 60:07


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Kathleen M. Buchheit, MD - Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 15, 2024 60:07


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

The Itch: Allergies, Asthma & Immunology
#87 :What biologic therapies are available for allergic conditions?

The Itch: Allergies, Asthma & Immunology

Play Episode Listen Later Oct 3, 2024 29:34


Are you curious about how biologic medications are transforming the treatment of asthma, eczema, allergies, and more? Dr. Perdita Permaul joins Dr. Gupta and Kortney to discuss the available biologic medications for allergic conditions. We walk through the eight biologics currently available for allergic diseases, explaining how these medications target different parts of the immune system to treat allergic conditions more effectively than traditional medications. Dr. Permaul explains how biologics have evolved since 2003 and how they are changing the way allergic conditions are treated. She also explains why some of the biologics treat multiple diseases, whereas some are only approved for one.  What we cover in our episode about the available biologics for allergic conditions How biologics work for allergic conditions: We unpack how biologic medications target specific parts of the immune system, reducing inflammation and improving the quality of life for patients with allergic diseases. History and evolution of biologics: Dr. Permaul walks us through the timeline of biologics, starting with Xolair in 2003 and how these treatments have expanded to target other conditions over time. Which biologics treat which conditions: From asthma and eczema to food allergies and nasal polyps, we break down which biologics are available and how they help patients with allergic conditions. Future of biologics: Dr. Permaul discusses the potential of biologics to be used for more conditions in the future, including ongoing research into food allergy treatments. Biologics Cheat Sheet Below is a list of the 8 biologics discussed in this episode. We have briefly outlined their mechanism of action along with the approved conditions and ages the drug is available for presecription.  Omalizumab (Xolair) Xolair works by binding to IgE to prevent allergic reactions. It has since been approved for chronic hives, nasal polyps, and food allergies. Allergic asthma: 6+ Chronic idiopathic urticaria (hives: 12+ Chronic rhinosinusitis with nasal polyps (CRSwNP): 18+ Food allergies:1+ Mepolizumab (Nucala) Targets and blocks interleukin-5 (IL-5) play a key role in the activation and priming of eosinophils, a type of white blood cell that causes inflammation in asthma. Eosinophilic Asthma: 6+ CRSwNP: 18+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Hypereosinophilic Syndrome: ≥6 months Reslizumab (Cinqair) Targets and blocks interleukin-5 (IL-5). Eosinophilic asthma: 18+ Benralizumab (Fasenra) Binds to the IL-5 receptor, preventing eosinophils from growing and causing inflammation. Eosinophilic asthma: 6+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Dupilumab (Dupixent) Targets and blocks IL-4 and IL-13 to reduce inflammation Asthma: 6+ Atopic Dermatitis: 6 months+ CRSwNP: 18+ Eosinophilic Esophagitis (EoE): 1+ (> 33 lbs) Approved for prurigo nodularis (PN): 18+ Tezepelumab (Tezspire) Blocks thymic stromal lymphopoietin (TSLP). Asthma: 12+ Tralokinumab (Adbry, Adtralza) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ Lebrikizumab (Ebglyss) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ (> 40 lbs) ________ This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Sanofi-Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement. Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Auf Herz und Nieren – Der Podcast für ein gutes Körpergefühl
#63 Chronische Nasennebenhöhlenentzündung mit Nasenpolypen: Wenn die Nase dauerhaft verstopft ist

Auf Herz und Nieren – Der Podcast für ein gutes Körpergefühl

Play Episode Listen Later Aug 20, 2024 41:11


Drückende Kopfschmerzen, eine verstopfte Nase, das Atmen fällt schwer, das Essen schmeckt nach nichts – die typischen Symptome einer Erkältung oder Coronainfektion. Zum Glück verschwinden sie meistens ein paar Tage später. Bei Stefan aber nicht, denn die Ursache ist eine andere: 22 Jahre lang leidet er unter einer chronischen Rhinosinusitis mit Nasenpolypen, kurz CRSwNP. Heute ist er so gut wie beschwerdefrei. Wir sprechen mit Stefan über Symptom-Frust und seinen Weg mit der chronischen Erkrankung. Außerdem erklärt HNO-Ärztin Dr. Sonja Spahn, welche Ursachen hinter der chronischen Rhinosinusitis mit Nasenpolypen stecken, alles über die Diagnosestellung und wie neue Therapieoptionen die Behandlung entscheidend verbessern können.

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Play Episode Listen Later Aug 16, 2024 18:09


Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

CME in Minutes: Education in Primary Care
Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

CME in Minutes: Education in Primary Care

Play Episode Listen Later Aug 16, 2024 18:09


Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

CME in Minutes: Education in Dermatology
Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

CME in Minutes: Education in Dermatology

Play Episode Listen Later Aug 16, 2024 18:09


Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 16, 2024 39:51


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 16, 2024 39:52


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 16, 2024 39:51


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 16, 2024 39:52


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 16, 2024 39:52


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 16, 2024 39:51


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later May 8, 2024 60:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 8, 2024 60:05


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 8, 2024 60:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 8, 2024 60:05


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 8, 2024 60:05


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 8, 2024 60:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Disclosure information is available at the beginning of the video presentation.

ADVENT On Air
Remission in CRSwNP

ADVENT On Air

Play Episode Listen Later Mar 29, 2024 19:06


Professor Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Professor Peter Hellings has received clinical trial funding and/or advisory board fees from Sanofi, Novartis, GlaxoSmithKline, Stallergenes, ALK, Viatris/Mylan. Doctor Stella Lee has received clinical trial funding and/or advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, OptiNose, Sanofi and Regeneron. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400409 v1.0 03/2024 MAT-US-2402818 v1.0 - P Expiration Date: 03/12/2026

ADVENT On Air
Exploring Loss of Smell in CRSwNP: Clinical Relevance and Patient Impact

ADVENT On Air

Play Episode Listen Later Jan 19, 2024 17:04


Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026

Scope It Out with Dr. Tim Smith
Episode 83: Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)

Scope It Out with Dr. Tim Smith

Play Episode Listen Later Dec 14, 2023 21:24


In this episode, host Dr. Marc Dubin speaks with Dr. Gurston Nyquist. They discuss his recently published article: Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Read the article in the International Forum of Allergy and Rhinology. Listen and subscribe for free on Apple Podcasts , Google Podcasts and Subscribe […]

En Kvart om Typ 2
Näspolypos - mer än bara nästäppa

En Kvart om Typ 2

Play Episode Listen Later Dec 14, 2023 15:17


I årets sista avsnitt gästar överläkare och professor Anders Cervin för att prata om kronisk rinosinuit med näspolyper (CRSwNP). Hur definieras det, vilka är symptomen och hur behandlar man tillståndet?

Hörgang
Chronische Rhinosinusitis mit nasalen Polypen - die Grundlagen

Hörgang

Play Episode Listen Later May 10, 2023 16:24


Die andauernde Entzündung der Schleimhäute von Nasen und Nasennebenhöhlen ist eine der häufigsten chronischen Entzündungen überhaupt. Dennoch wird weiterhin eifrig nach den Ursachen und Auslösern gesucht und das Repertoire an Therapien weiterentwickelt. So geht es in diesem Expertenpodcast auch um die Frage, was von den neuen Biologika zu halten ist. Als Experten zu Gast sind die HNO-Ärzte Frau Prof. Dr. Julia Eckl-Dorna und Herr Priv--Doz. Dr. Sven Schneider (beide MedUni Wien). Die Fragen stellt Martin Burger

allergytalk
CRSwNP Miniseries: Episode 1

allergytalk

Play Episode Listen Later Mar 23, 2023 14:23


Episode 1 provides an overview of the subtypes of CRSwNP and reviews the evidence for disparities in the burden of disease on minority and underserved populations and discusses the reasons for these disparities.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

allergytalk
CRSwNP Miniseries: Episode 3

allergytalk

Play Episode Listen Later Mar 23, 2023 15:06


Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

allergytalk
CRSwNP Miniseries: Episode 2

allergytalk

Play Episode Listen Later Mar 23, 2023 13:35


Episode 2 discusses the impact of air pollution and the environment on CRSwNP and how this disproportionately affects minority and underserved populations.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

PeerVoice Internal Medicine Video
Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Internal Medicine Video

Play Episode Listen Later Dec 13, 2022 22:32


Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Heart & Lung Video
Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Heart & Lung Video

Play Episode Listen Later Dec 13, 2022 22:32


Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Immunology & Infectious Disease Video
Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Immunology & Infectious Disease Video

Play Episode Listen Later Dec 13, 2022 22:32


Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Clinical Pharmacology Video
Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Clinical Pharmacology Video

Play Episode Listen Later Dec 13, 2022 22:32


Claire Hopkins, BMBCH, FRCS(ORLHNS), DM(Oxon) - Biologics in CRSwNP: Treatment Decisions in the Complex Patient

PeerVoice Clinical Pharmacology Audio
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later Nov 14, 2022 21:28


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Heart & Lung Audio
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Heart & Lung Audio

Play Episode Listen Later Nov 14, 2022 21:28


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Internal Medicine Audio
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Internal Medicine Audio

Play Episode Listen Later Nov 14, 2022 21:28


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Internal Medicine Video
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Internal Medicine Video

Play Episode Listen Later Nov 14, 2022 21:24


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Clinical Pharmacology Video
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Clinical Pharmacology Video

Play Episode Listen Later Nov 14, 2022 21:24


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Heart & Lung Video
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Heart & Lung Video

Play Episode Listen Later Nov 14, 2022 21:24


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Immunology & Infectious Disease Audio
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Immunology & Infectious Disease Audio

Play Episode Listen Later Nov 14, 2022 21:28


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Immunology & Infectious Disease Video
Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerVoice Immunology & Infectious Disease Video

Play Episode Listen Later Nov 14, 2022 21:24


Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 20, 2022 57:44


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 20, 2022 57:02


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 20, 2022 57:44


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 20, 2022 57:02


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 20, 2022 57:02


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Clinical Pharmacology CME/CNE/CPE Video
Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 20, 2022 57:44


Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 7, 2022 24:36


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 7, 2022 24:36


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 7, 2022 24:17


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 7, 2022 24:36


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 7, 2022 24:17


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 7, 2022 24:17


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 7, 2022 24:17


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 7, 2022 24:36


Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners' knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

FrequENTcy — AAO–HNS/F Otolaryngology Podcasts
What's important from the CRSwNP Biologics Trials

FrequENTcy — AAO–HNS/F Otolaryngology Podcasts

Play Episode Listen Later Jun 16, 2022 58:36


New on FrequENTcy! James “Whit” Mims, MD, and Joshua M. Levy, MD, MPH, share their insights on the clinical trials of various biologics for chronic rhinosinusitis with nasal polyps during the podcast, “What's Important from the CRSwNP Biologics Trials,” commissioned by the Allergy, Asthma, and Immunology Committee. 

Keeping Current
Evolving Care Pathways in the Management of CRSwNP: Role of Biologics

Keeping Current

Play Episode Listen Later Sep 16, 2021 35:20


Join Dr Bachert and our expert faculty for a discussion on the role of biologics in managing chronic rhinosinusitis with nasal polyps. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/958643?src=mkm_podcast_addon_958643

En Kvart om Typ 2
CRSwNP och Typ 2-inflammation

En Kvart om Typ 2

Play Episode Listen Later Jun 15, 2021 19:25


Välkommen till vårt femte avsnitt där vi bjudit in Professor Pär Stjärne från Karolinska Universitetssjukhuset för att diskutera kring CRSwNP och Typ 2-inflammation.Länk till diskuterade artiklar: Endotypes of chronic rhinosinusitis: Impact on management - PubMed (nih.gov)Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps - PubMed (nih.gov)Vid synpunkter, förslag på samtalsämnen eller frågor kan ni skriva till oss på enkvartomtyp2@sanofi.com  MAT-SE-2100718 (V.1.0.) June 2021

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 22, 2020 23:07


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 22, 2020 23:22


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 22, 2020 23:07


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 22, 2020 23:22


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 22, 2020 23:07


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 22, 2020 23:22


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 22, 2020 23:07


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 22, 2020 23:22


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Clinical Pharmacology CME/CNE/CPE Video
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 22, 2020 23:07


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 22, 2020 23:22


Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP